EJMK Ventures LLC Sells 5,952 Shares of Astrazeneca Plc $AZN

EJMK Ventures LLC reduced its stake in shares of Astrazeneca Plc (NYSE:AZN) by 64.4% during the first quarter, Holdings Channel reports. The institutional investor owned 3,297 shares of the company’s stock after selling 5,952 shares during the quarter. EJMK Ventures LLC’s holdings in Astrazeneca were worth $650,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of AZN. Natixis Advisors LLC grew its holdings in shares of Astrazeneca by 14.3% in the third quarter. Natixis Advisors LLC now owns 2,100,390 shares of the company’s stock worth $161,142,000 after purchasing an additional 262,465 shares during the last quarter. Guardian Capital LP raised its holdings in Astrazeneca by 31.0% during the 3rd quarter. Guardian Capital LP now owns 83,074 shares of the company’s stock valued at $6,373,000 after buying an additional 19,648 shares during the last quarter. Legacy Capital Group California Inc. bought a new stake in Astrazeneca during the 3rd quarter valued at $406,000. Focus Partners Advisor Solutions LLC boosted its position in Astrazeneca by 53.8% during the 3rd quarter. Focus Partners Advisor Solutions LLC now owns 10,307 shares of the company’s stock valued at $875,000 after buying an additional 3,604 shares during the period. Finally, Integral Health Asset Management LLC boosted its position in Astrazeneca by 50.0% during the 3rd quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock valued at $23,016,000 after buying an additional 100,000 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

More Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca’s cancer drug Enhertu won a new EU approval for HER2-positive solid tumors, its sixth EU indication, which could expand sales potential and support future revenue growth. AstraZeneca’s Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)
• Positive Sentiment: Several major brokers reiterated buy ratings on AZN, including Goldman Sachs, Bank of America, and JPMorgan, signaling continued analyst confidence in the stock. Goldman Sachs Reaffirms Buy Rating
• Positive Sentiment: Erste Group raised its FY2026 EPS estimate for AstraZeneca, suggesting expectations for stronger earnings than previously forecast.
• Neutral Sentiment: Zacks highlighted AZN as a strong momentum stock and compared it with Illumina, reinforcing that the shares remain on investors’ radar, but without a direct new catalyst. Here’s Why Astrazeneca (AZN) is a Strong Momentum Stock
• Negative Sentiment: Despite the positive company-specific news, AZN still traded lower as broader market weakness and a conflicting sell rating from Deutsche Bank likely weighed on sentiment. Deutsche Bank Sell Rating

Astrazeneca Stock Down 3.0%

Shares of NYSE AZN opened at $183.99 on Thursday. The firm has a fifty day simple moving average of $183.91 and a two-hundred day simple moving average of $187.58. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $285.35 billion, a PE ratio of 27.63, a price-to-earnings-growth ratio of 1.50 and a beta of 0.24.

Astrazeneca (NYSE:AZN) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The firm had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Equities analysts expect that Astrazeneca Plc will post 10.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Weiss Ratings cut shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 18th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research note on Tuesday. TD Cowen restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Finally, Bank of America reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday. Fourteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Astrazeneca presently has an average rating of “Moderate Buy” and an average price target of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.